CYP3A5*3 (n = 252) *1/*1 (n = 13) 10 76.9 0.09 0.54 *1/*3 (n = 64) 60 93.8 *3/*3 (n = 175) 163 93.1 CYP3A4*1b (n = 247) *1/*1 (n = 200) 189 94.5 0.08 0.48 *1/*1b (n = 33) 28 84.9 *1b/*1b (n = 14) 12 85.7 CYP3A4*22 (n = 252) * Abbreviations: ABCB1, ATP-binding cassette B1; CYP3A4/5, cytochrome P450 isoforms 4 and 5; DDI, drug-drug interactions. Abbreviations: ABCB1, ATP-binding cassette B1; CYP3A4/5, cytochrome P450 isoforms 4 and 5; SNP, single nucleotide polymorphism. Abbreviations: ABCB1, ATP-binding cassette B1; Adj, adjusted; CYP3A4/5, cytochrome P450 isoforms Table S5 . AKI occurrence for CYP3A4/5 and ABCB1 SNPs. Each CYP3A4/5 variant are presented in table below with total of patients presenting AKI during the first 15 days post-allogeneic HSCT. p < 0.05 was considered significant, and reported p values were adjusted for multiple comparisons using the Bonferroni method. CC (n = 56) 4 7.1 0.96 > 0.99 CT (n = 116) 7 6.0 TT (n = 50) 3 6.0 Table S6 . Cumulative incidence of aGVHD by CYP3A4/5 and ABCB1. Cumulative incidence of aGVHD occurrence, regardless of organ type, are presented below. Results are stratified by CYP3A4/5 and ABCB1, and grouped by all-grade, grade 2+, and grade 3+ aGVHD. p < 0.05 was considered significant. Abbreviations: ABCB1, ATP-binding cassette B1; aGVHD, acute graft-versus host disease; CYP3A4/5, cytochrome P450 isoforms 4 and 5.
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